Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Ann Neurol ; 79(5): 726-738, 2016 May.
Article in English | MEDLINE | ID: mdl-26891452

ABSTRACT

BACKGROUND: Quantitative in vivo imaging of myelin loss and repair in patients with multiple sclerosis (MS) is essential to understand the pathogenesis of the disease and to evaluate promyelinating therapies. Selectively binding myelin in the central nervous system white matter, Pittsburgh compound B ([11 C]PiB) can be used as a positron emission tomography (PET) tracer to explore myelin dynamics in MS. METHODS: Patients with active relapsing-remitting MS (n = 20) and healthy controls (n = 8) were included in a longitudinal trial combining PET with [11 C]PiB and magnetic resonance imaging. Voxel-wise maps of [11 C]PiB distribution volume ratio, reflecting myelin content, were derived. Three dynamic indices were calculated for each patient: the global index of myelin content change; the index of demyelination; and the index of remyelination. RESULTS: At baseline, there was a progressive reduction in [11 C]PiB binding from the normal-appearing white matter to MS lesions, reflecting a decline in myelin content. White matter lesions were characterized by a centripetal decrease in the tracer binding at the voxel level. During follow-up, high between-patient variability was found for all indices of myelin content change. Dynamic remyelination was inversely correlated with clinical disability (p = 0.006 and beta-coefficient = -0.67 with the Expanded Disability Status Scale; p = 0.003 and beta-coefficient = -0.68 with the MS Severity Scale), whereas no significant clinical correlation was found for the demyelination index. INTERPRETATION: [11 C]PiB PET allows quantification of myelin dynamics in MS and enables stratification of patients depending on their individual remyelination potential, which significantly correlates with clinical disability. This technique should be considered to assess novel promyelinating drugs. Ann Neurol 2016;79:726-738.

2.
J Virol ; 87(10): 6055-9, 2013 May.
Article in English | MEDLINE | ID: mdl-23514886

ABSTRACT

Progressive multifocal leukoencephalopathy (PML) is the main adverse effect of natalizumab. Detectable JC virus-specific effector memory T-cell (TEM) responses may indicate ongoing JCV replication. We detected JCV-specific TEM responses in blood of patients with multiple sclerosis (MS) treated with natalizumab, including 2 patients with PML. The frequency of detection of these responses increased with the time on natalizumab. Thus, a subset of MS patients exhibit immunological hallmarks of JCV replication during prolonged natalizumab therapy.


Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Biological Products/adverse effects , Immunologic Factors/adverse effects , JC Virus/immunology , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Virus Replication , Adult , Antibodies, Monoclonal, Humanized/administration & dosage , Biological Products/administration & dosage , Female , Humans , Immunologic Factors/administration & dosage , JC Virus/physiology , Middle Aged , Multiple Sclerosis/virology , Natalizumab , T-Lymphocytes/immunology
3.
Ann Neurol ; 69(4): 673-80, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21337603

ABSTRACT

OBJECTIVE: Imaging of myelin tracts in vivo would greatly improve the monitoring of demyelinating diseases such as multiple sclerosis (MS). To date, no imaging technique specifically targets demyelination and remyelination. Recently, amyloid markers related to Congo red have been shown to bind to central nervous system (CNS) myelin. Here we questioned whether the thioflavine-T derivative 2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PIB), which also binds to amyloid plaques, could serve as a myelin marker. METHODS: PIB fixation to myelin was studied by fluorescence in the normal and dysmyelinating mouse brain, as well as in the postmortem brain of MS patients. Positron emission tomography (PET) experiments were conducted using [¹¹C]PIB in baboons and in a proof of concept clinical study in 2 MS patients. RESULTS: Applied directly on tissue sections or after intraperitoneal injection, PIB stained CNS myelin, and the decrease in the level of fixation paralleled the amount of myelin loss in a dysmyelinating mutant. In normally myelinated areas of postmortem MS brain, demyelinated and remyelinated lesions were clearly distinguishable by the differential intensity of labeling observed with PIB. PET using intravenously injected radiolabeled [¹¹C]PIB imaged CNS myelin in baboons and humans. In MS patients, the dynamic analysis of PET acquisitions allowed quantitative assessment of demyelination. INTERPRETATION: PIB could be used as an imaging marker to quantify myelin loss and repair in demyelinating diseases.


Subject(s)
Benzothiazoles , Brain/diagnostic imaging , Brain/physiopathology , Carbon Radioisotopes , Demyelinating Diseases/diagnostic imaging , Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis/physiopathology , Positron-Emission Tomography , Aniline Compounds , Animals , Cadaver , Humans , Magnetic Resonance Imaging , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Nerve Regeneration , Papio anubis , Positron-Emission Tomography/methods , Thiazoles
SELECTION OF CITATIONS
SEARCH DETAIL